OUR BIOSIMILARS JOURNEY

The Biocon Group is driven by an unwavering purpose to deliver health equity through high-quality, affordable therapies that lower costs, increase access and improve treatment outcomes. As a diversified, global biopharmaceuticals enterprise, it is using the power of 'affordable innovation' to enable access to essential drugs for patients worldwide.

The Group is leveraging its scientific talent pool and global scale manufacturing capacities to develop, manufacture and commercialize generic APIs and formulations, biosimilars and novel biologics for some of the most debilitating diseases in the world. Its end-to-end capabilities -- from pipeline to production, and from drug discovery to drug delivery -- allow Biocon to deliver lifesaving medicines to patients in over 120 countries.

Biocon operates across four distinct business segments: Generics, managed by Biocon Limited; Biosimilars, managed by Biocon Biologics, Research Services, driven by Syngene, and Novel Biologics, overseen by Biocon.

While we develop cutting-edge therapies, we also care about the health of our planet and the welfare of our people and the communities in which we operate. All our business functions are committed to achieving sustainable growth and creating a positive impact on society.

From preserving the environment to reducing its carbon footprint and promoting the well-being of communities, employees and other stakeholders, Biocon is contributing to the larger goal of enabling the world to meet its targets under the United Nations Sustainable Development Goals (SDGs).

**Our Vision**
- To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners and healthcare systems across the globe.

**Our Values**
- Integrity and ethical behavior
- Performance-driven work culture
- Value creation through innovation and differentiation
- Quality through compliance and best practices
- Collaboration, teamwork and mutual respect

---

**BIOCON GROUP: QUICK FACTS**
- Bengaluru, India
- Employees 16,500+
- Commercial reach: 120+ countries
- Patents: 1,500+
- Biosimilars commercialized globally: 8
- CGMP approvals from international regulatory agencies: 100+
- Pharma companies served by service portfolio of Syngene: 15 of top 20

**FY2023 - FINANCIAL HIGHLIGHTS**
- Annual revenue: ₹115,501 mn ($1.4 bn)
- EBITDA: ₹28,876 mn ($351 mn)
- EBITDA margin: 25%
- Annual profit: ₹4,627 mn ($56 mn)
- Gross R&D spend: ₹11,953 mn ($146 mn)

**FY2023 - REVENUE BREAK-UP**
- Generics: 23%
- Biologics: 48%
- Research Services: 28%
Biocon Biologics Limited, a subsidiary of Biocon Ltd., is a unique, fully integrated, leading global biosimilars company committed to transforming healthcare and patients’ lives by enabling affordable access to high quality biologics worldwide. The Company has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, and other non-communicable diseases. It has a proven track record of success and has achieved several ‘firsts’ in the biosimilars sector. Biocon Biologics has commercialized eight biosimilars in several key Emerging Markets as well as Advanced Markets like U.S., EU, Australia, Canada and Japan. It recently acquired the global biosimilars business of its longstanding strategic partner Viatris, which is a historic milestone in its value creation journey.

Syngene International Limited, Biocon’s Research & Manufacturing Services business, delivers innovative scientific solutions to over 400 clients thus helping to accelerate drug development at an optimal cost. With a proven track record, it caters to diverse industries such as pharmaceuticals, biotechnology, nutrition, animal health, consumer goods and specialty chemicals. Its extensive scientific expertise, state-of-the-art infrastructure and stringent quality standards make it a preferred partner for innovative R&D solutions. Additionally, Syngene is listed on the Indian stock exchanges since 2015.

ESG - Sustainability is integral to Biocon’s business purpose, and the Company implements Environment, Social and Governance (ESG) programs in alignment with stakeholder expectations and the Company’s objectives.

As a science-driven Company, Biocon understands that human health is inextricably linked to the health of the planet. The principles of the 3Rs (reduce, reuse, recycle) are key aspects of its environmental strategy. Biocon’s commitment to diversity, equity and inclusion in the workplace is a cornerstone of its growth strategy. The Company continuously engages with its 16,500-strong workforce to make progress towards its ESG-focused goals. Through its Corporate Social Responsibility (CSR) programs, Biocon has worked on social upliftment, job-oriented advanced education, public infrastructure and lake rejuvenation.

Biocon’s ESG initiatives have led to its inclusion on the Dow Jones Sustainability Index and its induction into the S&P’s prestigious annual Sustainability Yearbook under the ‘industry mover’ category.
Biocon Foundation, the Corporate Social Responsibility arm of Biocon, has been working in the areas of socio-economic upliftment through programs aimed at improving healthcare access, education opportunities, environmental sustainability, rural and urban civic infrastructure since 2005. The Foundation’s comprehensive programs address the myriad developmental challenges facing India by delivering scalable solutions through innovative and sustainable models.

The Foundation has developed and nurtured strong relationships with the local community and other stakeholders. It has also nurtured long-term strategic partnerships with tertiary health providers to get technical support and with governments to fulfil mutual obligations in a private-public partnership (PPP) mode.

The Biocon Academy, founded in 2013, spearheads the Biocon Group’s CSR initiatives in technical and professional education for aspiring biotechnologists.

The Academy imparts rigorous academic learning and world-class industry-oriented training programs on applied aspects of various life sciences disciplines. In doing so, the Academy is helping create an enabling environment that moulds everyone into highly capable, forward-looking self-starters, equipped with the skills, experience and knowledge to move India forward.

Biocon Generics Business Leadership Team

Kiran Mazumdar-Shaw
Executive Chairperson

Siddharth Mittal
CEO & Managing Director

Indranil Sen
Chief Financial Officer

Maninder Kapoor Puri
Head, Human Resources

Abhijit Zutshi
Commercial Head, Global Generics

Nehal Vora
Commercial Head, Global APIs

Prasad Deshpande
Head, Supply Chain & Central Engineering

Manoj Kumar Pananchukunnath
Head, R&D & Regulatory Sciences

Sriram A V
Head, Quality

Arun Gupta
Head, Operations
Biocon (including Biocon Biologics)

Scored 52 in 2022 S&P Global’s Corporate Sustainability Assessment, inducted into S&P Global’s Sustainability Yearbook as an ‘Industry Mover’.

Continued listing in Dow Jones Sustainability Emerging Markets Index for the second consecutive year, ranking in the 90th percentile of Biotechnology companies.

EcoVadis awards Silver Medal for Sustainability accomplishments.

Received CDP scores of ‘B’ in Water and ‘C’ in Climate Change.


Biocon Limited

Won the Golden Peacock Award for Sustainability in 2022.

Best ESG Initiative to improve renewable energy during Annual ESG Summit and Awards 2022.

Biocon Biologics

Biocon Biologics’ Malaysia Facility won the prestigious ‘Bioprocessing Excellence in South Asia’ Award at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2023.

Won CII’s Special Appreciation IP Award 2022 for creating a large portfolio of patents & trademarks.


Won Greentech-Safety Excellence Award for excellent performance towards maintaining a safe workplace for employees and stakeholders.

Syngene

Won the Golden Peacock National Quality Award, 2023 from the Institute of Directors, India.

Named Best Contract Development and Manufacturing Organization (CDMO) at the IMAPAC Biopharma Awards.

Biocon Foundation

Received the Mahatma Award 2022 for Excellence in Social Good.

Won India Health and Wellness (IHW) Council’s Gold Award for Oral Cancer Screening Program.

Note: The information in this Fact Sheet is given as of the date mentioned, and Biocon does not assume any obligation to update the information on a frequent basis.

Last Updated: September 01, 2023